Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL) (PEARL)

This study has been completed.
Sponsor:
Information provided by:
Ligand Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00141323
First received: August 30, 2005
Last updated: August 8, 2011
Last verified: August 2011